Court dismisses Regeneron’s antitrust countersuit against Novartis
Novartis escaped an antitrust countersuit brought by Regeneron earlier this week, with a New York court dismissing the suit which had been filed in response to Novartis’ patent complaint.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
28 October 2021 The US Patent Trial and Appeal Board (PTAB) has granted a review of a Novartis syringe patent following a challenge from biotech giant Regeneron.
7 March 2022 Regeneron has failed to convince a Manhattan district court to drop a lawsuit claiming that it developed COVID-19 treatments using Allele’s fluorescent protein invention without its permission.
28 October 2021 The US Patent Trial and Appeal Board (PTAB) has granted a review of a Novartis syringe patent following a challenge from biotech giant Regeneron.
7 March 2022 Regeneron has failed to convince a Manhattan district court to drop a lawsuit claiming that it developed COVID-19 treatments using Allele’s fluorescent protein invention without its permission.
28 October 2021 The US Patent Trial and Appeal Board (PTAB) has granted a review of a Novartis syringe patent following a challenge from biotech giant Regeneron.
7 March 2022 Regeneron has failed to convince a Manhattan district court to drop a lawsuit claiming that it developed COVID-19 treatments using Allele’s fluorescent protein invention without its permission.
